Original Article
Predictive modeling of immunotherapy efficacy in driver gene-negative non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(2)
:24
.
(28 February 2026)
PKC-iota drives EGFR-TKI resistance in EGFR-mutated NSCLC by phosphorylating FASN to reprogram lipid metabolism
Translational Lung Cancer Research
2026;
15
(2)
:25
.
(28 February 2026)
Targeting NLRP3 inflammasome: a novel strategy for improving immune checkpoint inhibitor-associated pneumonitis
Translational Lung Cancer Research
2026;
15
(2)
:26
.
(28 February 2026)
Analysis of clinical and genomic features in a Chinese cohort with NRG1 variations: a retrospective study
Translational Lung Cancer Research
2026;
15
(2)
:27
.
(28 February 2026)
Higher proximity of PD-L1+ tumor cells to PD-1+ tissue-resident memory CD8 determines response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(2)
:28
.
(28 February 2026)
Association of CT-assessed sarcopenia and the development of immune-related adverse events and overall survival: a multistate survival analysis
Translational Lung Cancer Research
2026;
15
(2)
:29
.
(28 February 2026)
Correlation analysis between growth heterogeneity and genetic mutations in resected subsolid lung adenocarcinoma based on long-term computed tomography (CT) follow-up
Translational Lung Cancer Research
2026;
15
(2)
:30
.
(28 February 2026)
Impact of baseline brain metastases on survival and CNS progression in NSCLC patients treated with immune checkpoint inhibitors in real-world studies: a systematic review and meta-analysis
Translational Lung Cancer Research
2026;
15
(2)
:31
.
(28 February 2026)
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: efficacy and biomarker analysis of pemetrexed discontinuation
Translational Lung Cancer Research
2026;
15
(2)
:32
.
(28 February 2026)
Real-world insights into multidisciplinary management and outcomes of stage III (N2–3) non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(2)
:33
.
(28 February 2026)
Psychological distress in patients with detected pulmonary nodules from lung cancer screening
Translational Lung Cancer Research
2026;
15
(2)
:34
.
(28 February 2026)
A radiomics-based nomogram for preoperatively predicting the invasiveness of nodular lung adenocarcinoma: a multicenter study
Translational Lung Cancer Research
2026;
15
(2)
:35
.
(28 February 2026)
Molecular epidemiology and outcomes of EGFR exon 20 insertion in Korean patients with non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(2)
:36
.
(28 February 2026)
Multi-omics profiling reveals CDKN2A mutant early-onset lung squamous cell carcinoma with a “hot” tumor immune microenvironment
Translational Lung Cancer Research
2026;
15
(2)
:37
.
(28 February 2026)
Neoadjuvant immunochemotherapy in potentially resectable small cell lung cancer: a real-world retrospective analysis
Translational Lung Cancer Research
2026;
15
(2)
:38
.
(28 February 2026)
Brief Report
Neoadjuvant ALK tyrosine kinase inhibitor in patients with resectable locally advanced non-small cell lung cancer harboring ALK rearrangement
Translational Lung Cancer Research
2026;
15
(2)
:39
.
(28 February 2026)
Review Article
Current advances in mediastinal staging for non-small cell lung cancer: a narrative review
Translational Lung Cancer Research
2026;
15
(2)
:40
.
(28 February 2026)
Case Report
Pathological complete response following neoadjuvant chemoimmunotherapy in cancer of unknown primary: a case report
Translational Lung Cancer Research
2026;
15
(2)
:41
.
(28 February 2026)
Discovery of a novel ITPR2::KRAS fusion in large cell neuroendocrine lung cancer: a case report
Translational Lung Cancer Research
2026;
15
(2)
:42
.
(28 February 2026)
Convex-probe endobronchial ultrasound-guided cryobiopsy for pleural tumors: three case reports
Translational Lung Cancer Research
2026;
15
(2)
:43
.
(28 February 2026)
Letter to the Editor
A new therapeutic approach to KRAS mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition
Translational Lung Cancer Research
2026;
15
(2)
:44
.
(28 February 2026)
Osimertinib opens the door for patients with EGFR-mutated advanced non-small cell lung cancer and a poor performance status: comment on the OPEN/TORG2040 trial
Translational Lung Cancer Research
2026;
15
(2)
:45
.
(28 February 2026)
